
ARIZ: Developing early-stage cancer drug candidates for effective disease eradication.
Founded with a mission to eradicate cancer at its earliest stages, Ariz Precision Medicine focuses on developing innovative drug candidates that target the root causes of cancer. Utilizing a combination of biological and nanotechnologies, Ariz aims to prevent cancer growth and metastasis. Their core vision is to leverage precision medicine to create highly effective, individualized treatments for cancer patients, addressing the disease when it is most easily treatable.
Ariz Precision Medicine has garnered attention for its unique approach and promising early-stage drug candidates. The company is supported by a team of experts in oncology and biotechnology, and has attracted investment from leading venture capital firms specializing in healthcare innovation. Notable achievements include successful preclinical trials demonstrating the efficacy of their drug candidates. Ariz's impact lies in its potential to revolutionize cancer treatment, offering hope for more effective and personalized therapies.

OncoPrecision
oncoprecision.bio

Aria Pharmaceuticals

Zephyr AI
zephyrai.bio

Ariel Precision Medicine
arielmedicine.com

SEngine Precision Medicine

Predictive Oncology

Precision Health AI

Alphina Therapeutics

First Ascent Biomedical
firstascentbio.com

Known Medicine

Precision BioSciences

Curie.Bio
curie.bio

Empiri
empiricancer.com

Remedy Plan
remedyplan.com

Cartography Biosciences
cartography.bio
Companies similar to Ariz Precision Medicine include OncoPrecision, Aria Pharmaceuticals, Zephyr AI and Ariel Precision Medicine.
Ariz Precision Medicine was founded in 2015.
Ariz Precision Medicine's headquarters is located in Davis, CA, US.
Ariz Precision Medicine's most recent funding round was for $1M (USD) in March 2022.
As of Mar 16, 2022, Ariz Precision Medicine has raised a total of $2.7M (USD).
Ariz Precision Medicine has 2 employees as of Feb 5, 2024.